Clinical factor for clinicians to choose treatments to refractory ulcerative colitis patients, and the validity of the treatment.
Not Applicable
- Conditions
- refractory ulcerative colitis
- Registration Number
- JPRN-UMIN000025277
- Lead Sponsor
- agasaki university graduate school of Biomedecal Science Department of Gastroenterology and hepatology
- Brief Summary
The clinical response rates at 8 weeks were 74.0% in total, and 73.2% and 74.7% in the anti-TNF and TAC groups. Among the total cases, male sex was responded to the treatment. In the TAC group, high CRP increased the odds of treatment response. The male sex increased the odds of effectiveness only in the TNF group. TAC rather than anti-TNF therapy was an independent risk factor for relapse. A higher Mayo score at 8 weeks also significantly increased the risk for relapse in all cases.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patients who became observation impossible within 52 weeks after treatment starting 2. Patients whose treatment deviate from health insurance 3. The patient who are judged unsuitable by the researcher.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method